celebrating 20 years Performance highlights

OUR SIX CAPITALS

  • Acquired the remaining rights to the intellectual property and manufacturing know-how of the anaesthetics portfolio from AstraZeneca
  • Serialisation projects on track to meet new regulatory requirements designed to combat counterfeit medicines reaching patients
  • 45 products launched in 20 countries
  • R2 145 million invested in capital replacement and expansion projects
  • Officially opened the high containment suite at our Port Elizabeth site
  • Significantly reduced safety, health and environmental risks at the Moleneind site
  • Implemented first year of new Human Resources strategy
  • 49,5% women in the workforce
  • R66 million invested in training our employees
  • Zero occupational fatalities
  • Eighth consecutive year of participating in the International Mandela Day Initiative, with Aspen assisting nearly 470 000 beneficiates through 456 projects in 39 countries over this period
  • Significantly improved score in the FTSE/JSE Responsible Investment Index to 4
  • Maintained our level 4 Broad-based Black Economic Empowerment (“BBBEE”) rating in South Africa
  • “B – Management“ performance rating for 2017 Carbon Disclosure Project (“CDP”) and Water CDP
  • 3,2% of waste generated sent to landfill, a reduction from 4,5% in 2017
  • Resource conservation and optimisation projects contributed to a 5,0% reduction in water used
  • Successful refinancing of the Group’s debt portfolio
  • Strong operating cash flow per share conversion rate of 105%
  • R5 886 million (31%) of wealth created reinvested in the Group

Group revenue by business segment
(%)

Group revenue by customer geography
(%)


COMMERCIAL PHARMACEUTICALS

REGIONAL
BRANDS
revenue
R14 336 million
5%
increase*

KEY BRANDS

  • Circadin
  • Foxair
  • Mybulen
  • Tribuss
  • Zyloric
ANAESTHETICS
revenue
R8 332 million
21%
increase*

KEY BRANDS

  • Diprivan
  • EMLA
  • Naropin
  • Ultiva
  • Xylocaine
THROMBOSIS
revenue
R6 430 million
12%
increase*

KEY BRANDS

  • Arixtra
  • Fraxiparine
  • Fraxodi
  • Mono-embolex
  • Orgaran
HIGH POTENCY
& CYTOTOXICS
revenue
R4 172 million
9%
decrease*

KEY BRANDS

  • Alkeran
  • Eltroxin
  • Imuran
  • Ovestin
  • Purinethol

* on a CER basis

celebrating 20 years The value we create

Employees (R‘million)   Reinvested (R‘million)

Employees (R‘million)

 

Reinvested (R‘million)

     
R18 549 million
wealth created
Our sustainable business model creates long-term value
for our shareholders and the society in which we operate.
     

Providers of capital (R‘million)

 

Governments (R‘million)

Providers of capital (R‘million)   Governments (R‘million)
     

celebrating 20 years Our investment case

Aspen has a proud heritage dating back more than 160 years and is committed to sustaining life and promoting healthcare through increasing access to our high quality, affordable medicines and products

 

Broader opportunities

Established platform to further enhance therapeutically focused areas

Weighting towards emerging markets

 

Focus on technically complex products in specialist areas

Record of performance with post-patent molecules

World class production concentrated in steriles and other complex manufacture

 

Financial flexibility to take advantage of profitable opportunities

Strong correlation of earnings to cash flow

 

Established foundation of strong corporate governance

Active participant in the United Nations Global Compact (“UN Global Compact”) initiative

A constituent of the FTSE/JSE Responsible Investment Index

 

Grow sustainable stakeholder value

  Providing
employment
to more than
10 000
employees
worldwide
Delivered
NHEPS
compound
annual growth
rate (“CAGR”)
growth of 35% since listing
Supported
more than 220
Socio-Economic
Development
(“SED”) projects
during the year
Enhanced
access
to quality
affordable medicines
to patients
Significant
investment
in regions
in which we
operate
 
MORE ON OUR INVESTMENT CASE

celebrating 20 years Group Chief Executive's report

35%
CAGR
in NHEPS
since listing

Stephen Saad
Group Chief Executive
Stephen Saad

As we mark 20 years since our listing on the JSE, we celebrate our position as a global pharmaceutical company that makes a meaningful contribution to the many patients and consumers using our products each day. During the period under review we have integrated the acquired anaesthetics portfolios, strengthened our position in Emerging markets, focused on organic growth and performed a strategic review of our Nutritionals business. These actions continue the evolution of our strategy based on developing our portfolio of globally relevant IP, creating value and sustainability through our complex manufacturing capabilities and enabling access through our global footprint.

MORE ON THE GROUP CHIEF EXECUTIVE'S REPORT

celebrating 20 years Performance highlights

Intellectual capital

Our intellectual capital supports our commitment to increasing the number of lives that benefit from our focused therapeutic basket of high quality, affordable medicines and products

MORE ON OUR INTELLECTUAL CAPITAL

Manufactured capital

The continued investment in our API facilities and FDF manufacturing capabilities aimed at delivering flexible and scalable manufacturing and enhanced operational synergies is a key enabler in supporting our mission to produce high quality, affordable medicines and products, enhancing access to healthcare in over 150 countries

MORE ON OUR Manufactured CAPITAL

Human capital

Built on the foundation of our values and a commitment to the Group Code of Conduct, we strive to provide a safe, challenging and rewarding environment for each of our employees

MORE ON OUR Human CAPITAL

Social & relationship capital

Responsible corporate citizenship is more than a compliance requirement, it is fundamental to our objectives and the way we do business. We recognise that there are inseparable linkages between our sustainable growth, our relationships with our key stakeholders and our contribution to society in the broader context

MORE ON OUR Social & relationship CAPITAL

Natural capital

As a manufacturer of quality medicines, APIs and nutritional products, we are reliant on the conversion and use of natural capital in creating value for our stakeholders. We recognise that our operations directly and indirectly impact the environment. Our Environmental Management Protocol affirms our commitment to reducing our impact on the environment through responsible environmental management, conservation and protection across all of our operations

MORE ON OUR Natural CAPITAL

Financial capital

We aim to create value for all of our stakeholders by managing our financial capital in a commercially astute and diligent manner, thereby harnessing opportunities for long-term sustainable economic growth

MORE ON OUR Financial CAPITAL